Pediatric patients 3 months of age and older

Bacterial meningitis (pediatric patients 3 months of age and older only).

- In the absence of such data, local epidemiology and susceptibility patterns may be considered.

Table 1: Recommended Meropenem for injection (I.V.) Dosage Schedule for Pediatric Patients

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Dose (mg/kg)</th>
<th>Dose Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 months to 11 years</td>
<td>20 mg/kg (or 1 gram for pediatric patients weighing over 50 kg)</td>
<td>every 8 hours</td>
</tr>
</tbody>
</table>

- In the absence of such data, local epidemiology and susceptibility patterns may be considered.

Table 2: Recommended Meropenem for Injection (I.V.) Dosing Schedule for Pediatric Patients

<table>
<thead>
<tr>
<th>Type of Infection</th>
<th>Dose (mg/kg)</th>
<th>Up to a Maximum Dose</th>
<th>Dosing Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bacteroides fragilis</td>
<td>20 mg/kg</td>
<td>1 gram</td>
<td>every 8 hours</td>
</tr>
<tr>
<td>Skin and skin structure infections</td>
<td>10 mg/kg</td>
<td>500 mg</td>
<td>every 8 hours</td>
</tr>
<tr>
<td>Intra-abdominal infections</td>
<td>10 mg/kg</td>
<td>1 gram</td>
<td>every 8 hours</td>
</tr>
</tbody>
</table>

**CLINICAL PHARMACOLOGY**

8.5 Pediatric Use

Pediatric patients 3 months of age and older

Meropenem for injection (I.V.) (5.2) may be used in pediatric patients 3 months of age and older with normal renal function.

Table 3: Recommended Meropenem for injection (I.V.) Dosage Schedule for Pediatric Patients

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Dose (mg/kg)</th>
<th>Dose Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 months to 11 years</td>
<td>20 mg/kg (or 1 gram for pediatric patients weighing over 50 kg)</td>
<td>every 8 hours</td>
</tr>
</tbody>
</table>

- In the absence of such data, local epidemiology and susceptibility patterns may be considered.

Table 4: Table of Doses of Meropenem for Injection (I.V.)

<table>
<thead>
<tr>
<th>Type of Infection</th>
<th>Dose (mg/kg)</th>
<th>Dose Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bacteroides fragilis</td>
<td>20 mg/kg</td>
<td>1 gram</td>
</tr>
<tr>
<td>Skin and skin structure infections</td>
<td>10 mg/kg</td>
<td>500 mg</td>
</tr>
<tr>
<td>Intra-abdominal infections</td>
<td>10 mg/kg</td>
<td>1 gram</td>
</tr>
</tbody>
</table>

- In the absence of such data, local epidemiology and susceptibility patterns may be considered.

**ADVERSE REACTIONS**

- Intravenous infusion is to be given over 30 minutes.

**STABILITY AND STORAGE**

- Meropenem for injection (I.V.) should be administered by intravenous infusion and completed within 24 hours of reconstitution.

**CONTRAINDICATIONS**

- Meropenem for injection (I.V.) should be administered by intravenous infusion and completed within 24 hours of reconstitution.

**WARNINGS AND PRECAUTIONS**

- Use in Adult Patients with Renal Impairment

Meropenem for injection (I.V.) (5.2) may be used in pediatric patients 3 months of age and older with normal renal function.

**REFERENCES**

- Use in Adult Patients with Renal Impairment

Meropenem for injection (I.V.) (5.2) may be used in pediatric patients 3 months of age and older with normal renal function.

**REFERENCES**

- Use in Adult Patients with Renal Impairment

Meropenem for injection (I.V.) (5.2) may be used in pediatric patients 3 months of age and older with normal renal function.

**REFERENCES**

- Use in Adult Patients with Renal Impairment

Meropenem for injection (I.V.) (5.2) may be used in pediatric patients 3 months of age and older with normal renal function.

**REFERENCES**

- Use in Adult Patients with Renal Impairment

Meropenem for injection (I.V.) (5.2) may be used in pediatric patients 3 months of age and older with normal renal function.

**REFERENCES**

- Use in Adult Patients with Renal Impairment

Meropenem for injection (I.V.) (5.2) may be used in pediatric patients 3 months of age and older with normal renal function.

**REFERENCES**

- Use in Adult Patients with Renal Impairment

Meropenem for injection (I.V.) (5.2) may be used in pediatric patients 3 months of age and older with normal renal function.

**REFERENCES**

- Use in Adult Patients with Renal Impairment

Meropenem for injection (I.V.) (5.2) may be used in pediatric patients 3 months of age and older with normal renal function.

**REFERENCES**

- Use in Adult Patients with Renal Impairment

Meropenem for injection (I.V.) (5.2) may be used in pediatric patients 3 months of age and older with normal renal function.
Limited postmarketing experience indicates that if adverse events occur following treatment with meropenem for injection, they can be managed with supportive care. The effectiveness of supportive care is well documented in clinical studies.

2.3 Adverse Reactions (6.1) Clinical Pharmacology (12.3) and Clinical Studies (14.1)

There are no significant differences between the pharmacokinetics of meropenem in adults and children. Meropenem is primarily eliminated in the urine. Following a single 500 mg dose of meropenem for injection, the mean peak concentration of meropenem in serum was 3 mcg/mL at 0.5 hours. Following a single 500 mg dose of meropenem for injection, the mean peak concentration of meropenem in serum was 3 mcg/mL at 0.5 hours. Following a single 500 mg dose of meropenem for injection, the mean peak concentration of meropenem in serum was 3 mcg/mL at 0.5 hours. Following a single 500 mg dose of meropenem for injection, the mean peak concentration of meropenem in serum was 3 mcg/mL at 0.5 hours. Following a single 500 mg dose of meropenem for injection, the mean peak concentration of meropenem in serum was 3 mcg/mL at 0.5 hours. Following a single 500 mg dose of meropenem for injection, the mean peak concentration of meropenem in serum was 3 mcg/mL at 0.5 hours. Following a single 500 mg dose of meropenem for injection, the mean peak concentration of meropenem in serum was 3 mcg/mL at 0.5 hours. Following a single 500 mg dose of meropenem for injection, the mean peak concentration of meropenem in serum was 3 mcg/mL at 0.5 hours. Following a single 500 mg dose of meropenem for injection, the mean peak concentration of meropenem in serum was 3 mcg/mL at 0.5 hours. Following a single 500 mg dose of meropenem for injection, the mean peak concentration of meropenem in serum was 3 mcg/mL at 0.5 hours. Following a single 500 mg dose of meropenem for injection, the mean peak concentration of meropenem in serum was 3 mcg/mL at 0.5 hours. Following a single 500 mg dose of meropenem for injection, the mean peak concentration of meropenem in serum was 3 mcg/mL at 0.5 hours. Following a single 500 mg dose of meropenem for injection, the mean peak concentration of meropenem in serum was 3 mcg/mL at 0.5 hours. Following a single 500 mg dose of meropenem for injection, the mean peak concentration of meropenem in serum was 3 mcg/mL at 0.5 hours. Following a single 500 mg dose of meropenem for injection, the mean peak concentration of meropenem in serum was 3 mcg/mL at 0.5 hours. Following a single 500 mg dose of meropenem for injection, the mean peak concentration of meropenem in serum was 3 mcg/mL at 0.5 hours. Following a single 500 mg dose of meropenem for injection, the mean peak concentration of meropenem in serum was 3 mcg/mL at 0.5 hours. Following a single 500 mg dose of meropenem for injection, the mean peak concentration of meropenem in serum was 3 mcg/mL at 0.5 hours. Following a single 500 mg dose of meropenem for injection, the mean peak concentration of meropenem in serum was 3 mcg/mL at 0.5 hours. Following a single 500 mg dose of meropenem for injection, the mean peak concentration of meropenem in serum was 3 mcg/mL at 0.5 hours. Following a single 500 mg dose of meropenem for injection, the mean peak concentration of meropenem in serum was 3 mcg/mL at 0.5 hours.

3.2 times the MRHD based on body surface area comparisons.

Second generation offspring showed no meropenem-related changes in behavior or extraembryonic membranes compared to control offspring. However, the following in vitro data are available, but their clinical significance is unknown. At 80 mcg/mL and lower, meropenem was inactive against all the indicated pathogens in vitro. The following in vitro data are available, but their clinical significance is unknown. At 80 mcg/mL and lower, meropenem was inactive against all the indicated pathogens in vitro. The following in vitro data are available, but their clinical significance is unknown. At 80 mcg/mL and lower, meropenem was inactive against all the indicated pathogens in vitro. The following in vitro data are available, but their clinical significance is unknown. At 80 mcg/mL and lower, meropenem was inactive against all the indicated pathogens in vitro. The following in vitro data are available, but their clinical significance is unknown. At 80 mcg/mL and lower, meropenem was inactive against all the indicated pathogens in vitro. The following in vitro data are available, but their clinical significance is unknown. At 80 mcg/mL and lower, meropenem was inactive against all the indicated pathogens in vitro. The following in vitro data are available, but their clinical significance is unknown. At 80 mcg/mL and lower, meropenem was inactive against all the indicated pathogens in vitro. The following in vitro data are available, but their clinical significance is unknown. At 80 mcg/mL and lower, meropenem was inactive against all the indicated pathogens in vitro. The following in vitro data are available, but their clinical significance is unknown. At 80 mcg/mL and lower, meropenem was inactive against all the indicated pathogens in vitro. The following in vitro data are available, but their clinical significance is unknown. At 80 mcg/mL and lower, meropenem was inactive against all the indicated pathogens in vitro. The following in vitro data are available, but their clinical significance is unknown. At 80 mcg/mL and lower, meropenem was inactive against all the indicated pathogens in vitro. The following in vitro data are available, but their clinical significance is unknown. At 80 mcg/mL and lower, meropenem was inactive against all the indicated pathogens in vitro. The following in vitro data are available, but their clinical significance is unknown. At 80 mcg/mL and lower, meropenem was inactive against all the indicated pathogens in vitro. The following in vitro data are available, but their clinical significance is unknown. At 80 mcg/mL and lower, meropenem was inactive against all the indicated pathogens in vitro. The following in vitro data are available, but their clinical significance is unknown. At 80 mcg/mL and lower, meropenem was inactive against all the indicated pathogens in vitro. The following in vitro data are available, but their clinical significance is unknown. At 80 mcg/mL and lower, meropenem was inactive against all the indicated pathogens in vitro. The following in vitro data are available, but their clinical significance is unknown. At 80 mcg/mL and lower, meropenem was inactive against all the indicated pathogens in vitro. The following in vitro data are available, but their clinical significance is unknown. At 80 mcg/mL and lower, meropenem was inactive against all the indicated pathogens in vitro. The following in vitro data are available, but their clinical significance is unknown. At 80 mcg/mL and lower, meropenem was inactive against all the indicated pathogens in vitro. The following in vitro data are available, but their clinical significance is unknown. At 80 mcg/mL and lower, meropenem was inactive against all the indicated pathogens in vitro. The following in vitro data are available, but their clinical significance is unknown. At 80 mcg/mL and lower, meropenem was inactive against all the indicated pathogens in vitro. The following in vitro data are available, but their clinical significance is unknown. At 80 mcg/mL and lower, meropenem was inactive against all the indicated pathogens in vitro. The following in vitro data are available, but their clinical significance is unknown. At 80 mcg/mL and lower, meropenem was inactive against all the indicated pathogens in vitro. The following in vitro data are available, but their clinical significance is unknown. At 80 mcg/mL and lower, meropenem was inactive against all the indicated pathogens in vitro. The following in vitro data are available, but their clinical significance is unknown. At 80 mcg/mL and lower, meropenem was inactive against all the indicated pathogens in vitro. The following in vitro data are available, but their clinical significance is unknown. At 80 mcg/mL and lower, meropenem was inactive against all the indicated pathogens in vitro. The following in vitro data are available, but their clinical significance is unknown. At 80 mcg/mL and lower, meropenem was inactive against all the indicated pathogens in vitro. The following in vitro data are available, but their clinical significance is unknown. At 80 mcg/mL and lower, meropenem was inactive against all the indicated pathogens in vitro. The following in vitro data are available, but their clinical significance is unknown. At 80 mcg/mL and lower, meropenem was inactive against all the indicated pathogens in vitro. The following in vitro data are available, but their clinical significance is unknown.